E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
R/R Multiple Myeloma |
Mieloma múltiple recidivante o resistente |
|
E.1.1.1 | Medical condition in easily understood language |
Subjects with a type of blood cancer (multiple myeloma) that is either relapsed (comes back) or refractory (did not get better) after prior treatment. |
Sujetos con un tipo de cáncer de sangre (mieloma múltiple) que es en recaída (la enfermedad ha vuelto) o resistente (que no tiene mejoras) después del primer tratamiento |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028228 |
E.1.2 | Term | Multiple myeloma |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To characterize the safety and tolerability profiles of venetoclax combined with pomalidomide and dexamethasone when co-administered in subjects with R/R MM |
Para caracterizar los perfiles de seguridad y tolerabilidad de venetoclax en combinación con pomalidomida y dexametasona suministrados conjuntamente en sujetos con mieloma múltiple recidivante o resistente |
|
E.2.2 | Secondary objectives of the trial |
-To evaluate the anti-MM activity of co-administered venetoclax combined with pomalidomide and dexamethasone when co-administered in subjects with R/R MM
-To characterize the plasma pharmaacokinetics (PK) of venetoclax and pomalidomide when co-administered in subjects with R/R MM |
- Evaluar la activad anti mieloma múltiple de venetoclax en combinación con pomalidomida y dexametasona cuando suministrados conjuntamente en sujetos con mieloma múltiple recidivante o resistente - Caracterizar la farmacocinética en plasma del venetoclax y pomalidomida cuando suministrados conjuntamente en sujetos con mieloma múltiple recidivante o resistente |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Male of female, at least 18 years old • R/R MM with documented evidence of progression during or after the subject's last treatment regimen based on the investigator's determination of the International Myeloma Working Group (IMWG) criteria • Measurable disease, defined by at least 1 of the following disease activity criteria: - serum M-protein ≥ 1.0 g/dL (≥ 10 g/L) for immunoglobulin (Ig)G MM - serum M-protein ≥ 0.5 g/dL (≥ 5 g/L) for IgA, IgD, IgE, and IgM MM - urine M-protein ≥ 200 mg/24 hours - serum-free light chain (FLC) ≥ 10 mg/dL provided serum FLC ratio is abnormal • Has received at least 1 prior line of therapy • Must meet all of the following prior antimyeloma treatment parameters: - subject must have received at least 2 consecutive cycles of lenalidomide or a lenalidomide-containing regimen - subject must be refractory to lenalidomide - subject must have been exposed to a proteasome inhibitor alone or in combination with another agent - subject must have had a response of PR or better to prior therapy based on the investigator's determination of response as defined by IMWG criteria • Has t(11;14) status determined by an analytically validated fluorescent in situ hybridization (FISH) assay per central laboratory testing of a bone marrow aspirate sample and meets the following criteria: - For Part 1: MM subjects independent of cytogenetic profile - For Part 2, Arm A: subject must be t(11;14) positive - For Part 2, Arm B: subject must be t(11;14) negative • (ECOG) performance status ≤ 2 |
- Hombre o mujer, de al menos 18 años - Mieloma múltiple recidivante o resistente con signos documentados de progresión durante o después de la última pauta de tratamiento del paciente según la determinación del investigador de los criterios del International Myeloma Working Group (IMWG). - Enfermedad mensurable, definida por al menos 1 de los siguientes criterios de actividad de la enfermedad: • Proteína M sérica ≥ 1,0 g/dl (≥ 10 g/l) para MM de inmunoglobulina (Ig)G. • Proteína M sérica ≥ 0,5 g/dl (≥ 5 g/l) para MM IgA, IgD, IgE e IgM. • Proteína M en orina ≥ 200 mg/24 horas. • Cadenas ligeras libres (CLL) en suero ≥ 10 mg/dl (100 mg/l) siempre que el cociente de CLL en suero sea anómalo. - Han recibido previamente al menos 1 línea de tratamiento. - Deben cumplir todos los siguientes parámetros del tratamiento previo contra el mieloma: • El paciente debe haber recibido al menos 2 ciclos consecutivos de lenalidomida o una pauta con lenalidomida. • El paciente debe ser resistente a lenalidomida. • El paciente debe haber estado expuesto a un inhibidor del proteasoma solo o en combinación con otro fármaco. • El paciente debe haber tenido una respuesta de RP o mejor al tratamiento previo basándose en la determinación de la respuesta por el investigador según lo definido por los criterios del IMWG. - El paciente tiene un estado t(11;14) determinado mediante un análisis de hibridación in situ con fluorescencia (FISH) validado analíticamente según el laboratorio central de una muestra de aspirado de médula ósea y cumple los criterios siguientes: • En la parte 1: Pacientes con MM independientes del perfil citogenético. • En la parte 2, grupo A: el paciente debe presentar positividad de t(11;14). • En la parte 2, grupo B: el paciente debe presentar negatividad de t(11;14). • Estado funcional del Eastern Cooperative Oncology Group (ECOG) ≤ 2. |
|
E.4 | Principal exclusion criteria |
• previous treatment with venetoclax or other BCL-2 inhibitors, or previous treatment with pomalidomide • known sensitivity to any IMiDs • allogenic or syngeneic stem cell transplant within 6 months before the first dose of study drug or active ongoing graft versus host disease • autologous stem cell transplant within 12 weeks before the first dose of study drug • known meningeal involvement of MM |
- tratamiento previo con venetoclax u otros inhibidores de BCL-2, o tratamientos previos con pomalidomida - sensibilidad conocida a cualquier fármaco inmunomodulador - transplante de células madre allogénico o singénico en los 6 meses antes de la primera dosis del medicamento del estudio o enfermedad activa de injerto en huesped - transplante de células madre autólogo en las 12 semanas antes de la primera dosis del fármaco en estudio - afectación meníngea conocida de mieloma múltiple |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall Response Rate |
Ratio de respuesta global |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Dependent on individual subjects response to therapy. All subjects with be treated until progressive disease, unacceptable toxicity, or other reason for discontinuation |
Dependiendo de la respuesta individual de cada sujeto a la terapia. Cada sujeto se tratará hasta la progresión de la enfermedad, toxicidad inaceptable, o cualquier otra razón para la discontinuación |
|
E.5.2 | Secondary end point(s) |
- Secondary Endpoints are: • Progression-free survival (PFS) • Duration of response (DOR) • Time-to-progression (TTP |
Objetivos secundarios - Supervivencia libre de progresión - Duración de la respuesta - Tiempo hasta la progresión |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Will be monitored throughout the subject's participation in the study. |
Se monitorizará a lo largo de la participación del sujeto en el estudio |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end-of-study is defined as the last subject’s last visit, or date of the last follow-up contact, whichever is later. |
El final del estudio está definido como la última visita del último sujeto o la fecha del último contacto de seguimiento, la que más tarde sea. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 0 |